New Insights from the EUROPA trial by Icro Meattini et al.
Kristina Jankovic, Medical Oncology Resident at the University Clinical Center Niš, shared a recent article by Icro Meattini on X:
“New Insights from the EUROPA trial in The Lancet.
In women aged 70+ with low-risk, early breast cancer, radiotherapy vs endocrine therapy after BCS showed:
- Better HRQoL at 24 months (-3.4 vs -9.8, p=0.045).
- Fewer adverse events (67% vs 85%).”
Authors: Icro Meattini, Maria Carmen De Santis, Luca Visani, Marta Scorsetti, Alessandra Fozza, Bruno Meduri, Fiorenza De Rose, Elisabetta Bonzano, Agnese Prisco, Valeria Masiello, Eliana La Rocca, Ruggero Spoto, Carlotta Becherini, Gladys Blandino, Luca Moscetti, Riccardo Ray Colciago, Riccardo A Audisio, Etienne Brain, Saverio Caini, Marije Hamaker, Orit Kaidar-Person, Matteo Lambertini, Livia Marrazzo, Calogero Saieva, Tanja Spanic, Vratislav Strnad, Sally Wheelwright, Philip M P Poortmans and Lorenzo Livi
Kristina Jankovic, MD, is a Medical Oncology Resident at the University Clinical Center Niš, where she works at the Oncology Clinic. Her primary interests include breast cancer, innovative cancer therapies, oncofertility, and hereditary cancers. She is a member of ESMO, ASCO, and the European School of Oncology (ESO).
Icro Meattini is a Consultant in the Radiation Oncology Department at Florence University Hospital in Italy and an Associate Professor of Radiation Oncology at the University of Florence. He heads the Breast Unit at Florence University Hospital, with primary research interests in breast cancer, multimodal treatments, oligometastatic disease, cardiac toxicity prevention, partial breast irradiation, and optimizing clinical trial research.
For more updates, follow OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023